Ira J Dunkel MD

Clinical Trials

• Chemotherapy in Treating Patients With Retinoblastoma Start of enrollment: 1995 May 01

  Completed

  Phase 2

• High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Start of enrollment: 1997 Sep 01

  Completed

  Phase 2

• Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers Start of enrollment: 1998 Sep 01

  Completed

  Phase 2

• Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma Start of enrollment: 2003 Feb 01

  Completed

  Not Applicable

• Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 May 06

  COMPLETED

  PHASE3

• Research on the Environment and Children's Health: Retinoblastoma Start of enrollment: 2003 Aug 01

  Completed

• Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life

  RECRUITING

• Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors Start of enrollment: 2008 Oct 01

  Completed

  Phase 1

• Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas Start of enrollment: 2009 Jun 01

  Completed

  Phase 2

• Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System Start of enrollment: 2009 Feb 25

  Completed

  Phase 1

• External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas Start of enrollment: 2009 Oct 30

  Completed

  Phase 2

• Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors Start of enrollment: 2010 Jan 01

  Completed

  Phase 1

• Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Start of enrollment: 2010 Jul 07

  ACTIVE_NOT_RECRUITING

  PHASE1, PHASE2

• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas Start of enrollment: 2012 Feb 01

  Completed

  Phase 1, Phase 2

• Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27

  COMPLETED

  PHASE2

• Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery Start of enrollment: 2014 Apr 01

  Terminated

  Phase 2

• p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors Start of enrollment: 2013 Aug 01

  Completed

  Phase 1

• Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG Start of enrollment: 2017 Apr 04

  ACTIVE_NOT_RECRUITING

  NA

• Phase I Study of APX005M in Pediatric Central Nervous System Tumors Start of enrollment: 2018 Mar 01

  ACTIVE_NOT_RECRUITING

  PHASE1

• A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma Start of enrollment: 2022 Jul 01

  RECRUITING

  PHASE1

  Roles: Contact

• A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Start of enrollment: 2020 Jan 17

  ACTIVE_NOT_RECRUITING

  PHASE1, PHASE2

  Roles: Contact, Principal Investigator

• Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery Start of enrollment: 2019 Jul 25

  RECRUITING

  PHASE1, PHASE2

  Roles: Contact

• LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Start of enrollment: 2016 Nov 02

  Recruiting

  Phase 2, Phase 3

  Roles: Contact

• 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Start of enrollment: 2022 Apr 04

  ACTIVE_NOT_RECRUITING

  PHASE2

  Roles: Principal Investigator, Contact

• HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma Start of enrollment: 2022 Jul 27

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Join now to see all